The Efficacy and Safety of a New Enteric-Coated Formulation of Fluoxetine Given Once Weekly During the Continuation Treatment of Major Depressive Disorder
J Clin Psychiatry 2000;61:851-857
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: A simple, once-weekly dosing
regimen could be a convenient alternative for many patients
during long-term treatment of depression. Such a strategy might
also be effective for improving medication compliance and the
outcome of continuation treatment. The safety and effectiveness
of a new formulation of enteric-coated fluoxetine (90 mg) given
once weekly was tested during the continuation treatment of major
Method: Patients meeting DSM-IV criteria
for major depressive disorder with modified 17-item Hamilton
Rating Scale for Depression (HAM-D-17) scores >= 18
and Clinical Global Impressions-Severity of Illness scale (CGI-S)
scores >= 4 were treated 13 weeks with open-label 20 mg/day of
fluoxetine in a multicenter U.S. study. Responders (N = 501) were
randomly assigned to receive 20 mg of fluoxetine daily, placebo,
or 90 mg of enteric-coated fluoxetine weekly for 25 weeks of
double-blind continuation treatment. The primary efficacy measure
was the percentage of patients who relapsed. Time to relapse was
tested over the 25-week continuation period using log-rank
analyses of the Kaplan-Meier estimates of relapse rates.
Additional analyses of efficacy included comparison of change
from baseline to endpoint for the HAM-D-17, CGI-S, and HAM-D-28
subscales by last observation carried forward (LOCF). Safety
measures included comparison of treatment-emergent adverse
events, both spontaneous and solicited (using the Association for
Methodology of Documentation in Psychiatry-Module 5), vital
signs, and laboratory measures.
Results: Relapse rates for patients
assigned to fluoxetine, either 20 mg daily or 90 mg weekly, were
significantly lower than for placebo by log-rank analysis and
LOCF analyses of secondary efficacy measures. Efficacy did not
significantly differ between the 2 active drug groups by these
measures. Enteric-coated fluoxetine at a once-weekly dose of 90
mg was well tolerated, and its safety profile was similar to that
of daily 20 mg of fluoxetine.
Conclusion: The formulation of
enteric-coated fluoxetine taken once weekly is effective, safe,
and well tolerated for continuation treatment of depression in
patients who responded to acute treatment with 20 mg/day of
fluoxetine. Monitoring during long-term treatment for evidence of
sustained remission is important regardless of dosing regimen.